Current Cardiology Reviews最新文献

{"title":"Heartfelt Transformations: An Exploratory Study of Self-Reported Personality Changes Following Heart Transplantation.","authors":"Ibrahim T I Makhlouf, Basma Alomar, Lamees Alsalehi, Mohamedanas Mohamedfaruk Patni","doi":"10.2174/011573403X491559260824065641","DOIUrl":"https://doi.org/10.2174/011573403X491559260824065641","url":null,"abstract":"<p><strong>Introduction: </strong>Heart transplantation is a life-saving procedure with well-documented physiological outcomes. However, its psychosocial implications, particularly personality changes, remain underexplored. This study aims to explore post-transplant personality changes in heart recipients and possible contributing factors.</p><p><strong>Methods: </strong>19 heart transplant recipients were interviewed via semi-structured video calls. Interviews focused on changes in personality traits, emotions, preferences, spirituality, and selfawareness. Thematic analysis and quantitative coding were used to identify recurring patterns. Statistical tests were applied to evaluate potential correlations with donor-recipient variables.</p><p><strong>Results: </strong>17 of 19 recipients reported at least one personality change. Common themes included increased empathy, altered food preferences, aversion to meat, heightened spirituality, and greater motivation. Female recipients and those with a donor of the opposite gender or a >10-year age gap experienced more changes on average. The age gap effect was statistically significant (p = 0.00098). Emotional changes were the most frequently reported domain.</p><p><strong>Discussion: </strong>This study highlights the prevalence and complexity of personality changes following heart transplantation. These findings suggest that heart transplants may influence recipient identity beyond physiological recovery.</p><p><strong>Conclusion: </strong>These findings are exploratory and intended to generate hypotheses for future controlled studies. Greater awareness of this phenomenon can improve post-transplant care and patient well-being.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Effects of Electronic Cigarettes and Heated Tobacco Products on Vascular Stiffness: A Systematic Review and Meta-Analysis.","authors":"Anna Bragina, Natalia Druzhinina, Yulia Rodionova, Ilya Shvedov, Kirill Novikov, Irakli Loriya, Dinara Natkina, Sakinat Abdullayeva, Sergey Muradov, Arina Kozlova, Oleg Kluev, Valery Podzolkov","doi":"10.2174/011573403X481596260810100109","DOIUrl":"https://doi.org/10.2174/011573403X481596260810100109","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular diseases remain the leading cause of mortality worldwide. Emerging risk factors, such as electronic cigarettes and Heated Tobacco Products (HTPs), may contribute to vascular damage. This systematic review and meta-analysis aimed to evaluate the association between nicotine-containing electronic cigarettes and HTPs and arterial stiffness.</p><p><strong>Methods: </strong>The study followed PRISMA and Cochrane Collaboration guidelines and was registered in the PROSPERO database (ID: CRD42023446895). PubMed, Scopus, Google Scholar, and eLIBRARY databases from January 1, 2000 to July 30, 2024. Outcomes included Pulse Wave Velocity (PWV), Augmentation Index (AIx), Cardio-Ankle Vascular Index (CAVI), ankle- brachial index (ABI).</p><p><strong>Results: </strong>From 3,705 abstracts, 9 experimental studies (n=190) were included. CAVI and ABI indices were excluded due to limited data. The PWV analysis included 6 studies (n=133) and demonstrated a significant increase following exposure to nicotine-containing products (SMD=1.71 [95% CI: 0.23-3.19, p=0.031]). The AIx analysis included 9 studies (n=190) and also demonstrated a significant increase (SMD=1.05 [95% CI: 0.34-1.76, p=0.008]). Metaregression analyses showed no significant moderating effects of publication year, age, or sex. However, small-study effects and substantial heterogeneity were identified.</p><p><strong>Discussion: </strong>The study's findings are consistent with previous studies and suggest possible vascular effects of nicotine-containing electronic cigarettes and HTPs. However, limitations require cautious interpretation, and long-term studies are warranted.</p><p><strong>Conclusion: </strong>Evidence suggests a possible acute increase in arterial stiffness following exposure to nicotine-containing electronic cigarettes and HTPs compared with non-smokers or nicotinefree electronic cigarette users, but certainty is limited by high heterogeneity, small samples, and methodological variability.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outpatient Cardiovascular Disease Consultation Wait Times in the United States-Mexico Border Regions.","authors":"Ramzi Ibrahim, Kevin N Griffith, Hoang Nhat Pham, Mahmoud Abdelnabi, Christopher Kanaan, Xuan Ci Mee, Ghee Kheng Lim, George Bcharah, Timothy Barry, Justin Z Lee, Juan Farina, Chadi Ayoub, Reza Arsanjani, Kwan Lee","doi":"10.2174/011573403X414641251205150658","DOIUrl":"https://doi.org/10.2174/011573403X414641251205150658","url":null,"abstract":"<p><strong>Introduction: </strong>Access to timely healthcare in disadvantaged areas remains essential to achieving equitable health outcomes, especially in regions facing structural and social vulnerabilities. We evaluated assessment wait times for cardiovascular disease consultations in USMexico border regions compared to non-border regions among US Veterans.</p><p><strong>Methods: </strong>This longitudinal panel of counties included all cardiovascular consultations referred from the U.S. Veterans Health Administration to community medical centers from 2014 to 2020. Consultations were classified as either a US-Mexico border or a non-border region based on the Veterans' home addresses. Multivariable linear regression analyses were performed to evaluate the impact of border status on average wait times. ARIMA modeling was completed to estimate forecasted wait times during the COVID-19 pandemic. The primary outcomes were the average wait times in days for consultation scheduling, completion, and total wait time from approval to consultation completion.</p><p><strong>Results: </strong>Wait times for cardiovascular disease consultations were not higher in US-Mexico border counties than in non-border regions. For electrophysiology consultations specifically, border counties exhibited significantly shorter total wait times (coeff = -10.81 days, p=0.008). Additionally, while the COVID-19 pandemic led to increased total wait times in non-border areas (actual=42.49 days versus predicted=28.47 days), total wait times in border regions remained stable during this period.</p><p><strong>Conclusions: </strong>US-Mexico border region status does not appear to result in longer wait times for cardiovascular disease consultations, with the exception of shorter wait times for electrophysiology services. These findings suggest that wait times are not a primary barrier within the VHA community care system in border areas.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary Management of Failed Tricuspid Valve Prosthesis.","authors":"Haytham Allaham, Diljon Chahal, Mukta Srivastava, Seyed Hossein Aalaei-Andabili, Anuj Gupta, James Brown","doi":"10.2174/011573403X472500260812052613","DOIUrl":"https://doi.org/10.2174/011573403X472500260812052613","url":null,"abstract":"<p><p>Failure of tricuspid valve prostheses is an increasingly encountered and complex clinical problem. Patients often present with advanced comorbidities, progressive right ventricular dysfunction, and prohibitive surgical risk. Despite growing burden, high-quality evidence and clear guideline-directed strategies remain limited. This narrative review summarizes contemporary approaches to the management of failed tricuspid valve prostheses, which include traditional redosurgical re-intervention, minimal invasive and beating-heart surgical techniques, and transcatheter valve-in-valve and valve-in-ring implantation, as well as emerging therapies for failed transcatheter tricuspid devices. Redo tricuspid valve surgery has historically carried substantial perioperative risk, although outcomes have improved at experienced centers, particularly with less invasive surgical approaches. Transcatheter valve-in-valve and valve-in-ring procedures demonstrate a high procedural success rate and favorable early outcomes in selected patient profiles with failed bioprosthetic valves or annuloplasty rings. However, durability beyond short to mid-term remains uncertain, especially in younger individuals. Given the heterogeneity of the prosthesis types and patients' profiles, the management should be individualized. A multidisciplinary Heart Team approach that integrates surgical risk, right ventricular function, prosthesis characteristics, and anatomic considerations is essential to optimize outcomes in this high-risk patient population. Given the limited and heterogeneous nature of currently available evidence, this review was designed as a clinically focused narrative review rather than a formal systematic review or meta-analysis.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conduction System Pacing in Cardiac Amyloidosis: Current Evidence, Outcomes, and Knowledge Gaps.","authors":"Newton Nguyen Khoa Bui Le, Nicholas Fanous, Rajesh Natarajan Subbiah","doi":"10.2174/011573403X467446260728042517","DOIUrl":"https://doi.org/10.2174/011573403X467446260728042517","url":null,"abstract":"<p><strong>Introduction: </strong>Conduction System Pacing (CSP) is a physiologic alternative to right ventricular pacing and may be advantageous in Cardiac Amyloidosis (CA), where conduction disease and septal infiltration are common.</p><p><strong>Methods: </strong>A systematic review of 9 published studies, including 7 case reports or small series and 2 retrospective cohorts, identified 59 patients with CA who underwent CSP.</p><p><strong>Results: </strong>Left bundle branch area pacing was the predominant technique. Implant success was high overall, ranging between 80 and 95%, with acute capture thresholds between 0.5 and 1.0 V at 0.5 ms and stable performance during follow-up. Paced QRS duration was typically 120-140 ms, representing QRS narrowing in most patients. In individual cases, improvement in New York Heart Association class, natriuretic peptide levels, and left ventricular ejection fraction was observed; however, cohort data demonstrated stable systolic function (45.5% to 41.9%) and unchanged NT-proBNP concentrations. Heart failure hospitalization occurred in 17-35% of patients, and mortality was limited to disease progression in AL amyloidosis. No device-related complications were reported.</p><p><strong>Discussion: </strong>CSP in cardiac amyloidosis appears technically feasible and electrically stable in CA and may mitigate the deleterious effects of chronic right ventricular pacing. However, reproducible and longitudinal clinical benefit has not been demonstrated.</p><p><strong>Conclusion: </strong>Conduction system pacing in cardiac amyloidosis is feasible with favourable electrical parameters, but its clinical utility remains uncertain. Larger prospective registries are required to define its role relative to conventional biventricular pacing.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Takotsubo Syndrome Using the InterTAK Criteria: Insights from Inter- TAK-Defined Patients (A Systematic Review).","authors":"Matthias Dullaert, Fee Van Langenhove, Said Hachimi-Idrissi","doi":"10.2174/011573403X481585260812113355","DOIUrl":"https://doi.org/10.2174/011573403X481585260812113355","url":null,"abstract":"<p><strong>Introduction: </strong>To synthesize contemporary evidence on epidemiology, triggers and risk factors, pathophysiology, clinical presentation, diagnosis, management patterns, and outcomes in Takotsubo Syndrome (TTS) restricted to studies using the International Takotsubo (InterTAK) Diagnostic Criteria.</p><p><strong>Methods: </strong>A PRISMA‑guided systematic review of major bibliographic databases was performed, limited to studies published between 2019 and October 2024. Pre‑specified criteria were: Inter- TAK diagnosis, English language, and minimum sample size ≥ 30. No meta‑analysis was initially planned due to heterogeneity; however, to report more precisely on in-hospital mortality, we focused on a minimal meta-analysis based on high-quality publications.</p><p><strong>Results: </strong>Across studies, approximately 78% of participants were female, with reported mean ages ranging from 54 to 79 years. Physical triggers were most frequent and associated with higher rates of cardiogenic shock and mortality. Emotional triggers had the most favourable short-term outcomes, while unknown-trigger cases more often presented with arrhythmia. T-wave inversion and ST-segment changes were the most common Electrocardiogram (ECG) findings. Several noninvasive diagnostic tools showed high accuracy in differentiating TTS from ACS. Management was largely supportive and heart-failure/ACS-oriented. In-hospital mortality ranged from 5% in general cardiology series to > 60% in ICU cohorts. Early ventricular arrhythmias occurred predominantly within 48 hours and were predicted by QTc. Long-term follow-up revealed variable mortality rates but frequent persistent subclinical dysfunction despite recovery of Left Ventricular Ejection Fraction (LVEF). Persistent Left Ventricular Global Longitudinal Strain (LV-GLS) impairment at 3-6 months was associated with adverse long-term outcomes.</p><p><strong>Discussion: </strong>This review exclusively focused on studies applying the InterTAK Diagnostic Criteria. A major strength of this review is its diagnostic consistency. The epidemiological profile of TTS in the included studies closely aligns with prior large-scale registry data, particularly the InterTAK Registry (2), which demonstrated a predominance among postmenopausal women and a mean presentation age in the late sixties. This diversity in presentation underscores the importance of early, structured assessment whenever TTS is suspected. Bedside clinical scores may improve early triage of suspected TTS, particularly when angiography is delayed or inconclusive.</p><p><strong>Conclusion: </strong>TTS is a heterogeneous condition with diverse presentations, evolving diagnostic tools, and important prognostic implications. Large, prospective studies are needed to refine diagnosis, validate prognostic tools, and develop effective targeted therapies to improve outcomes.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in T1 Mapping for Cardiac MRI: Comprehensive Review of Techniques, Clinical Applications, Artificial Intelligence Integration, and Future Perspectives.","authors":"Mariem Dali, Narjes Benameur, Wafa Baccouch, Nadjia Kachenoura, Moncef Aloui, Salam Labidi","doi":"10.2174/011573403X435977260731064734","DOIUrl":"https://doi.org/10.2174/011573403X435977260731064734","url":null,"abstract":"<p><strong>Introduction: </strong>The use of cardiovascular magnetic resonance (CMR) T1 mapping is becoming the dominant method for quantitatively characterizing diffuse tissue abnormalities in the myocardium that cannot be detected by traditional late gadolinium enhancement (LGE). This review provides a comprehensive overview of recent technical advances in T1 mapping, including a critical evaluation of the different acquisition techniques and their clinical applications. It also examines the role of artificial intelligence (AI) in the interpretation of T1 mapping data. It discusses its potential impact on clinical implementation and the translation of T1 mapping into routine practice.</p><p><strong>Methods: </strong>A narrative review of the current literature related to T1 mapping was conducted using PubMed and Scopus. The search focused on T1 mapping techniques, including their development, normal ranges, clinical applications, and AI approaches to T1 mapping image analysis.</p><p><strong>Results: </strong>Differentiation among T1 mapping techniques (MOLLI, SHMOLLI, SASHA, SMART1Map) based on accuracy, robustness, and acquisition limitations can influence their use in clinical practice. The literature indicates considerable variability in the T1 normal range, which is attributed to sequence type, magnetic field strength, manufacturer, and patient characteristics, making it challenging to create a universal reference range. From a clinical perspective, T1 mapping helps evaluate cardiomyopathy, infiltrative and ischemic disease (including myocarditis), as it shows improved ability to detect diffuse myocardial involvement compared to LGE alone. AI algorithms may be useful for automating segmentation, reducing motion artefacts, and improving measurement consistency.</p><p><strong>Discussion: </strong>Despite its considerable clinical value, the broader implementation of T1 mapping remains challenged by variations in acquisition protocols and the lack of universally standardized reference values. Artificial intelligence may help mitigate some of these limitations by enhancing measurement consistency and facilitating automated image analysis. Nevertheless, further validation studies and greater harmonization across imaging platforms are still necessary before AI-driven approaches can be fully integrated into routine clinical practice.</p><p><strong>Conclusion: </strong>T1 mapping represents a valuable non-invasive technique for myocardial tissue characterization. Although AI has the potential to enhance reproducibility, improve image quality, and streamline workflow, broader clinical adoption remains contingent upon further efforts. These include the standardization of acquisition and analysis methods, validation in large multicenter cohorts, and the attainment of regulatory approval.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem Cell and Gene Therapies in Congenital Heart Disease: A Systematic Review.","authors":"Shruti Tomar, Abhishek Sharma, Vikas Kumar","doi":"10.2174/011573403X487301260723154428","DOIUrl":"https://doi.org/10.2174/011573403X487301260723154428","url":null,"abstract":"<p><strong>Introduction: </strong>To systematically evaluate the safety, feasibility, and efficacy of stem cell and gene therapies in congenital heart disease (CHD).</p><p><strong>Methods: </strong>The search included PubMed/MEDLINE, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov databases for human and animal studies published in English from January 2000 through June 2025. Preclinical and clinical studies on stem cell/gene therapy for CHD that reported structural, functional, and safety outcomes were assessed. Due to heterogeneity, data were narratively synthesized.</p><p><strong>Results: </strong>Of 1, 128 records, 30 studies met the inclusion criteria, comprising 14 clinical studies, 16 preclinical investigations, and an additional 8 ongoing trials. Most clinical studies focused on single-ventricle physiology, especially HLHS. The interventions demonstrated generally reassuring short-term safety profiles, with none reporting malignant changes or cell-related organ toxicities. Efficacy outcomes were inconsistent, as some trials demonstrated improvements in ventricular function parameters with long-term benefits, whereas others showed no functional improvements despite a favorable safety profile. No definitive clinical trials of gene therapy in CHD have yet been completed.</p><p><strong>Discussion: </strong>Although the number of clinical trials is limited, the collective findings suggest potential translational applicability of regenerative therapy in the management of congenital heart diseases. The available evidence is limited by small and heterogeneous sample sizes. Future strategies would need to focus on multicenter clinical trials and the application of newer modalities to provide durable responses.</p><p><strong>Conclusions: </strong>Stem cell therapies for CHD have demonstrated encouraging biologic signals and generally reassuring early safety data. Rigorous multicenter randomized controlled trials with standardized endpoints and long-term follow-up are needed to define their actual therapeutic effectiveness.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148807850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Early Detection: The Role of Cardiac Imaging and Early Biomarkers in Immune Checkpoint Inhibitor-Related Myocarditis.","authors":"Shubhika Jain, Anaiya Singh, Samarth Goyal, Viraj Panchal, Mansunderbir Singh, Hunter Smeltzer, Priyanka Anvekar, Ashini Modi, Emma K Mayfield, Sahith Reddy, Kalgi Modi, Kavitha Beedupalli","doi":"10.2174/011573403X439081260717112519","DOIUrl":"https://doi.org/10.2174/011573403X439081260717112519","url":null,"abstract":"<p><p>The advent of Immune Checkpoint Inhibitors (ICIs) has marked a significant paradigm shift in oncology, leading to improved outcomes in various malignancies. However, this therapeutic advance is affected by the emergence of immune-related adverse events, among which myocarditis, though infrequent, carries a high mortality rate. The nonspecific clinical manifestations and lack of uniform diagnostic criteria frequently result in delayed recognition, underscoring the need for enhanced strategies for early detection. This review synthesizes current evidence on the application of cardiac imaging and circulating biomarkers in the identification of ICI-associated myocarditis. We critically evaluate the diagnostic performance of established imaging modalities such as Cardiac Magnetic Resonance (CMR) and transthoracic echocardiography, while exploring the advanced techniques, including hybrid PET-CMR imaging and myocardial strain analysis. Parallelly, we examine the diagnostic and prognostic utility of conventional and emerging biomarkers, ranging from high-sensitivity troponins and natriuretic peptides to exploratory molecular signatures such as cytokine profiles and exosomal microRNAs. Collectively, these modalities offer the potential for a multimodal, risk-stratified diagnostic framework that may facilitate timely therapeutic intervention. Emphasis is placed on integrating clinical, imaging, and molecular data to inform evidence-based surveillance algorithms. As the oncologic use of ICIs expands, refining our capacity to detect cardiac immune toxicity at a subclinical stage remains imperative to optimizing both oncologic and cardiovascular outcomes.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148807909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-Analysis of TAVR Versus SAVR in Bicuspid Valve: Mortality, Complications, and Long-Term Outcomes.","authors":"Vamsikalyan Borra, Sidhartha Gautam Senapati, Arankesh Mahadevan, Roopesh Vempati, Ketan Tamirisa, Nithya Borra, Ikechukwu Ogbu","doi":"10.2174/011573403X463733260721120148","DOIUrl":"https://doi.org/10.2174/011573403X463733260721120148","url":null,"abstract":"<p><strong>Introduction: </strong>Bicuspid Aortic Valve (BAV) is the most common congenital heart disease and often causes aortic stenosis in younger adults. There are few prospective randomized trials comparing Transcatheter Aortic Valve Replacement (TAVR) and Surgical Aortic Valve Replacement (SAVR) in BAV patients, since these patients are usually excluded from major studies because of their complex anatomy. A meta-analysis to compare clinical outcomes between TAVR and SAVR in people with BAV was conducted.</p><p><strong>Methods: </strong>PubMed, Google Scholar, and SCOPUS were searched for studies published up to December 2023 that compared TAVR and SAVR in patients with BAV. The main outcomes that were examined were mortality, atrial fibrillation, permanent pacemaker implantation, stroke, respiratory complications, and acute kidney injury. Forward and backward citation searches were also used. Random-effects models were used to calculate pooled odds ratios (ORs) with 95% confidence intervals, and heterogeneity was assessed using the I² statistic. Sensitivity analyses were performed by removing one study at a time.</p><p><strong>Results: </strong>The analysis included seven studies with a total of 96,430 BAV patients. Of these, 41,110 had TAVR and 55,320 had SAVR. Patients who had TAVR were less likely to experience in-hospital respiratory complications, bleeding or need for transfusion, and new-onset atrial fibrillation. However, they were more likely to need a permanent pacemaker. There were no significant differences between the groups in short-term mortality, stroke, or acute kidney injury.</p><p><strong>Discussion: </strong>Lower peri-procedural morbidity with TAVR likely reflects its minimally invasive nature, whereas higher pacemaker rates may relate to bicuspid valve anatomy and conduction system vulnerability.</p><p><strong>Conclusion: </strong>TAVR appears to be a reasonable alternative to SAVR in carefully selected BAV patients, but randomized trials and long-term follow-up remain necessary.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}